Fez Ujjainwalla, CBO, Terray Therapeutics
Dr. Ujjainwalla joined Terray Therapeutics in 2022 and is responsible for the company’s business development and pipeline strategy as well as alliance management. Prior to joining the company, Fez was Director of Business Development and Licensing (BD&L) at Merck & Co., Inc. He joined Merck in 1995 as Senior Research Chemist and rose to the rank of Executive Director of Chemistry before joining BD&L. He has led discovery programs from inception to early clinical development, delivering eight preclinical development candidates of which three proceeded to clinical trials – including the discovery of the first-in-class small molecule MC4R agonist, MK-0493, for the treatment of obesity. He has also led the search, scientific evaluation and execution of licensing deals and strategic partnerships, establishing numerous transactions across a range of agreement types including target focused R&D licenses as well as dominant platform licenses for DNA-Encoded Library Technology, mRNA Display Technology and Organoid Technology. Fez earned his BSc in Chemistry and PhD in Organic Chemistry from Imperial College of Science, Technology & Medicine and completed his postdoctoral training at The University of Texas at Austin. He is an author on over 85 publications and patents.
